OKYO Pharma (NASDAQ:OKYO) stock jumped 14% Wednesday after announcing encouraging Phase 2 clinical trial results for urcosimod, their investigational drug aimed at neuropathic corneal pain (NCP). The ...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

The Andhra Pradesh State Council of Higher Education (APSCHE) has released the AP ECET 2025 Phase 2 counselling schedule.

BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a ...

After the Grenfell fire there are many lessons to be learned. Architects and manufacturers should be able to demonstrate they ...

Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 ...

It’ll be the 5th and 6th ones they’ve built so far. This partnership has been in the making since 2022, and Bright Community Trust broke ground on their first houses here in Gainesville in 2024. The ...

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

Amirco Properties, a real estate company, is expected to break ground on the 4-acre, multi-building development—dubbed ...